Novo Nordisk has suggested that it’ll discontinue the Protaphane InnoLet human insulin (rys) 100 IU/mL injection multidose cartridge on February 1, 2025. The gadget is used significantly among the many aged as a result of it’s simple to make use of and girls with gestational diabetes mellitus.
Novo Nordisk is advising individuals to substitute Protaphane Penfill human insulin 100 IU/mL (ARTG 169635) or Humulin NPH biosynthetic human isophane insulin 100 IU/mL injection multidose cartridge (ARTG 39662).
Between now and February 1, the Therapeutic Items Administration is advising pharmacists to make use of a Critical Shortage Substitution Instrument (SSSI) to dispense the Protaphane Penfill human insulin (rys) 100 IU/mL injection multidose cartridge with out the necessity for a brand new prescription. These penfills will want a brand new insulin supply gadget and people utilizing it might want to know how one can insert cartridges and use the brand new pen safely and precisely.
Folks dwelling with diabetes who can be affected by the discontinuation are suggested to ask their well being professionals about altering over to the urged replacements as quickly as doable.
Diabetes Australia has raised issues in regards to the discontinuation, together with entry to the alternative gadget.
Whereas data for pharmacists and healthcare professionals has now been launched in regards to the alternative, not all prescribers and pharmacists will see this data in a well timed method. Considerations have additionally been raised about the price of the additional time or appointments that folks dwelling with diabetes might have with their GPs, educators or endocrinologists to acquire new scripts or gadget directions.
Diabetes Australia is searching for assurances that there can be sufficient alternative units out there when required; that there can be no value to individuals dwelling with diabetes; and that the substitute units can be out there throughout Australia together with in regional, rural, and Aboriginal and Torres Strait Islander communities.
Diabetes Australia will proceed its advocacy on behalf of the estimated 30,000 individuals utilizing Innolet and replace the neighborhood as data turns into out there.
Additional data is offered from the Therapeutic Items Administration web site.
